@naturebiotech:
Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment https://www.nature.com/...
@naturebiotech:
Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment https://www.nature.com/...
New in Nature Biotechnology: CCDHI Co-Associate Director of AI John Hickey and collaborators introduce a single-cell approach to uncover barriers to therapeutic antibody delivery in solid tumors.
🔗 duke.is/naturebiotech
New in Nature Biotechnology: CCDHI Co-Associate Director of AI John Hickey and collaborators introduce a single-cell approach to uncover barriers to therapeutic antibody delivery in solid tumors.
🔗 duke.is/naturebiotech
www.nature.com/articles/s41...
www.nature.com/articles/s41...
👉🏻 https://rdcu.be/cbKfx
It was really fun working on this project with @MolecularPrtnrs. You can check out the pre-print here:
https://www.biorxiv.org/content/10.1101/2020.08.25.256339v2
👉🏻 https://rdcu.be/cbKfx
It was really fun working on this project with @MolecularPrtnrs. You can check out the pre-print here:
https://www.biorxiv.org/content/10.1101/2020.08.25.256339v2
rdcu.be/cwZKr insidehighered.com/news/2021/09/0…
rdcu.be/cwZKr insidehighered.com/news/2021/09/0…
@NatureBiotech
! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇
www.nature.com/articles/s41...
@NatureBiotech
! We introduce SEED-Selection, a powerful method that enables high-efficiency enrichment of T cells edited at multiple loci in a single step 🧵👇
www.nature.com/articles/s41...